AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31342318 — intervention group
Group type: COMPARATOR
Intervention: Stable performance
Number of subjects: 25
Study 31342318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline
Number of subjects: 25
Study 31342473 — intervention group
Group type: EXPERIMENTAL
Intervention: BougieCap (Ovesco Endoscopy AG)
Number of subjects: 50
Study 31342533 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week web-based individualised exercise program
Number of subjects: 44
Study 31342832 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical DWI lesions
Number of subjects: 0
Study 31342832 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-lesion heterogeneity analysis
Number of subjects: 0
Study 31342851 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemental health therapy
Number of subjects: 0
Study 31342904 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-i Coach mobile app intervention
Number of subjects: 38
Study 31343500 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor strength in women with radiographic knee osteoarthritis (mean = -17.6 N)
Number of subjects: 641
Study 31343500 — intervention group
Group type: COMPARATOR
Intervention: Knee extensor strength in controls (mean = +4.5 N)
Number of subjects: 641
Study 31343500 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor strength in women without radiographic knee osteoarthritis
Number of subjects: 641
Study 31343500 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in extensor strength before incident pain
Number of subjects: 641
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (0.1-10.0 mg/kg) every 2 weeks in 8-week cycles for up to 96 weeks
Number of subjects: 270
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with treatment-related AEs of any grade
Number of subjects: 270
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with treatment-related AEs of grade 3 or more
Number of subjects: 270
Study 31343665 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab treatment without treatment-related AEs
Number of subjects: 270
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with Eastern Cooperative Oncology Group performance status of 0
Number of subjects: 270
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with liver metastases
Number of subjects: 270
Study 31343665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with bone metastases
Number of subjects: 270
Study 31344312 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of aquagenic pruritus (AP) in ET patients
Number of subjects: 396
Study 31344674 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliCare mental health apps, 7-week intervention, with a 30-min coaching call before use and a 10-min follow-up coaching call 3 weeks later.
Number of subjects: 50
Study 31344678 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback in a virtual reality game intervention
Number of subjects: 34
Study 31344678 — intervention group
Group type: COMPARATOR
Intervention: Control group (typically developing children)
Number of subjects: 34
Study 31345012 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily until disease progression
Number of subjects: 66
Study 31345133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid filtration (neurapheresis therapy) for up to 24 hours
Number of subjects: 13
Study 31345133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid filtration (neurapheresis therapy)
Number of subjects: 13
Study 31345207 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused cardiac ultrasound (FCU) performed by general practitioners (GPs)/GP registrars after a training programme comprising 20 supervised FCU examinations
Number of subjects: 100
Study 31345207 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac ultrasound by specialists
Number of subjects: 100
Study 31345240 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM group (surgery)
Number of subjects: 24
Study 31345639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of MMR-containing vaccine (Priorix or Priorix-Tetra)
Number of subjects: 1887
Study 31345639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MMR-containing vaccine (Priorix or Priorix-Tetra)
Number of subjects: 1887
Study 31345639 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of MMR vaccine given later in life
Number of subjects: 1887
Study 31345639 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of MMR vaccine given anytime over the 10-year period
Number of subjects: 1887
Study 31345776 — intervention group
Group type: EXPERIMENTAL
Intervention: MARD
Number of subjects: 1105
Study 31345776 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD
Number of subjects: 1105
Study 31345776 — intervention group
Group type: EXPERIMENTAL
Intervention: SAID
Number of subjects: 1105
Study 31345776 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRD
Number of subjects: 1105
Study 31345776 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDD
Number of subjects: 1105
Study 31345970 — intervention group
Group type: EXPERIMENTAL
Intervention: Known atrial fibrillation (AF) patients not treated with oral anticoagulation
Number of subjects: 1470
Study 31345970 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed atrial fibrillation (AF) patients
Number of subjects: 1470
Study 31345970 — intervention group
Group type: COMPARATOR
Intervention: Patients with known AF
Number of subjects: 1470
Study 31346584 — intervention group
Group type: EXPERIMENTAL
Intervention: A&T intensive (A&T-I) areas with specialized IYCF training, job aids, and regular supportive supervision
Number of subjects: 0
Study 31346584 — intervention group
Group type: COMPARATOR
Intervention: A&T non-intensive (A&T-NI) areas with standard government training and supervision
Number of subjects: 0
Study 31346584 — intervention group
Group type: EXPERIMENTAL
Intervention: FLW-level performance outcomes
Number of subjects: 0
Study 31346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus erlotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg plus erlotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus erlotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus crizotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 14
Study 31346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus ipilimumab
Number of subjects: 14
Study 31346932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 62
Study 31346977 — intervention group
Group type: EXPERIMENTAL
Intervention: OdySight visual acuity module
Number of subjects: 120
Study 31346977 — intervention group
Group type: EXPERIMENTAL
Intervention: OdySight contrast sensitivity module
Number of subjects: 120
Study 31346977 — intervention group
Group type: EXPERIMENTAL
Intervention: OdySight Amsler Grid module
Number of subjects: 120
Study 31347100 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Number of subjects: 62
Study 31347100 — intervention group
Group type: COMPARATOR
Intervention: MDI (multiple daily injections of insulin)
Number of subjects: 62
Study 31347926 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 0
Study 31347926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31348866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical lysis of adhesions and manipulation under anesthesia for LOM after ACL reconstruction
Number of subjects: 58
Study 31348866 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without LOM
Number of subjects: 58
Study 31348866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for LOM after ACL reconstruction
Number of subjects: 58
Study 31348987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy
Number of subjects: 0
Study 31349390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 31349390 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg 3 times daily
Number of subjects: 0
Study 31349390 — intervention group
Group type: COMPARATOR
Intervention: Bosentan or macitentan
Number of subjects: 0
Study 31349390 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (postoperative use)
Number of subjects: 0
Study 31349390 — intervention group
Group type: COMPARATOR
Intervention: General PAH pharmacotherapy
Number of subjects: 0
Study 31349844 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making and Renal Supportive Care (SDM-RSC) intervention
Number of subjects: 102
Study 31349866 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg oral dispersible tablet)
Number of subjects: 250
Study 31349866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to zinc tablet)
Number of subjects: 250
Study 31350082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioinductive collagen implant for rotator cuff repair
Number of subjects: 0
Study 31350159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-related knowledge score assessed by the modified General Nutrition Knowledge Questionnaire (0-56 points)
Number of subjects: 116
Study 31350159 — intervention group
Group type: EXPERIMENTAL
Intervention: General dietary recommendations and dietary behaviors to reduce cardiovascular disease and cancer
Number of subjects: 116
Study 31350159 — intervention group
Group type: EXPERIMENTAL
Intervention: Health problems related to lower intake of fruit, vegetables, and fiber; knowledge about antioxidants vitamins
Number of subjects: 116
Study 31350201 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/Oxaliplatin regimen (capecitabine 825 mg/m2) with concurrent radiotherapy (RT)
Number of subjects: 20
Study 31350241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during the periconception period and pregnancy.
Number of subjects: 350
Study 31350241 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer conception strategies offered as part of the woman-centred programme.
Number of subjects: 350
Study 31350241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes measured include HIV seroconversion rates and pregnancy and infant outcomes.
Number of subjects: 350
Study 31350241 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted with participants.
Number of subjects: 350
Study 31350244 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD assessment including clinical and neuropsychological assessments, blood sample collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, multimodal MRI scans, glucose metabolism and amyloid positron emission tomography.
Number of subjects: 800
Study 31350251 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life in Adult Cancer Survivors; EORTC-QLQ-C30
Number of subjects: 3000
Study 31350251 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol-5 dimensions (EQ-5D)
Number of subjects: 3000
Study 31350251 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy, social support, social networks, and lifestyle questionnaires
Number of subjects: 3000
Study 31350251 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 3000
Study 31350306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) monotherapy (1.8 mg/kg IV every 3 weeks up to 8 cycles)
Number of subjects: 10
Study 31350306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) monotherapy
Number of subjects: 10
Study 31350329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (56-day course)
Number of subjects: 18
Study 31350784 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effects
Number of subjects: 0
Study 31350784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo effects
Number of subjects: 0
Study 31350784 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy violation
Number of subjects: 0
Study 31351076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation (MI-E) titration
Number of subjects: 27
Study 31351210 — intervention group
Group type: EXPERIMENTAL
Intervention: Super selective intra-arterial cerebral infusion (SIACI) of bevacizumab
Number of subjects: 1
Study 31351210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of bevacizumab
Number of subjects: 1
Study 31351210 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide with an investigational agent
Number of subjects: 1
Study 31351267 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended targeted treatment (RTT)
Number of subjects: 309
Study 31351267 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling
Number of subjects: 309
Study 31351371 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 45
Study 31351452 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with low tidal volume ventilation and additional regional anesthesia (for abdominal surgery)
Number of subjects: 69
Study 31351452 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with low tidal volume ventilation (for peripheral surgery)
Number of subjects: 69
Study 31351452 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal surgery
Number of subjects: 69
Study 31351452 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral surgery
Number of subjects: 69
Study 31351862 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP-224 with SBRT (8 Gy on day 0) and cyclophosphamide (200 mg/m2)
Number of subjects: 15
Study 31351922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.67 mg GLS-5300
Number of subjects: 75
Study 31351922 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg GLS-5300
Number of subjects: 75
Study 31351922 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg GLS-5300
Number of subjects: 75
Study 31351922 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of GLS-5300
Number of subjects: 75
Study 31352035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dlco percent predicted decrease (continuous variable)
Number of subjects: 1806
Study 31352035 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized severe impairment in Dlco
Number of subjects: 1806
Study 31352417 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantification of cardiovascular calcifications on planning CT scans
Number of subjects: 16000
Study 31352417 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-cohort analysis among cohort members diagnosed with a CVD event during follow-up (n≈200) and a random sample of the baseline cohort (n≈600)
Number of subjects: 16000
Study 31352425 — intervention group
Group type: EXPERIMENTAL
Intervention: ePIPAC-OX (92 mg/m²)
Number of subjects: 0
Study 31352486 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use for 7 days followed by 6 days of abstinence
Number of subjects: 109
Study 31352850 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor with rituximab
Number of subjects: 24
Study 31352850 — intervention group
Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2
Number of subjects: 24
Study 31353243 — intervention group
Group type: EXPERIMENTAL
Intervention: glecaprevir-pibrentasvir
Number of subjects: 25
Study 31353243 — intervention group
Group type: COMPARATOR
Intervention: NAT-negative grafts
Number of subjects: 25
Study 31353421 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic exposure (ratio of time on biologic relative to time in BRASS cohort)
Number of subjects: 1395
Study 31353854 — intervention group
Group type: COMPARATOR
Intervention: microRNA expression analysis in serum of AOPD patients
Number of subjects: 50
Study 31353964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 31353964 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31354330 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone self-administration
Number of subjects: 0
Study 31354810 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D
Number of subjects: 40
Study 31354810 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1500 mg/daily) plus placebo
Number of subjects: 40
Study 31354810 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements
Number of subjects: 40
Study 31354960 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized eHealth intervention with daily goals via ExSed application for 90 days after discharge.
Number of subjects: 540
Study 31354960 — intervention group
Group type: COMPARATOR
Intervention: Standard postsurgical rehabilitation guidance.
Number of subjects: 540
Study 31355009 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Sleep Apnea Predictor (ESAP)
Number of subjects: 43
Study 31355009 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 43
Study 31355009 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) testing
Number of subjects: 43
Study 31355176 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernutrition assessment
Number of subjects: 0
Study 31355205 — intervention group
Group type: EXPERIMENTAL
Intervention: AXA2678
Number of subjects: 20
Study 31355205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 31355467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat alone
Number of subjects: 335
Study 31355467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with azacitidine
Number of subjects: 335
Study 31355467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with docetaxel
Number of subjects: 335
Study 31355467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with carboplatin + paclitaxel
Number of subjects: 335
Study 31355467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with gemcitabine
Number of subjects: 335
Study 31355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfactory AFP decline (AFP normalized within the first 2 measures after chemotherapy)
Number of subjects: 131
Study 31355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsatisfactory AFP decline (AFP half-life >7 days after chemotherapy)
Number of subjects: 131
Study 31355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 11 years or older with standard risk 2 disease
Number of subjects: 131
Study 31355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with satisfactory decline vs unsatisfactory decline
Number of subjects: 131
Study 31356140 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 125
Study 31356140 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 125
Study 31356143 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-Ts (Tumor-associated antigen cytotoxic T cells) infused at three dose levels: 1, 2, and 4 × 10^6 cells
Number of subjects: 15
Study 31356143 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-Ts at the highest dose level
Number of subjects: 15
Study 31356143 — intervention group
Group type: COMPARATOR
Intervention: Prior therapy (control)
Number of subjects: 15
Study 31356143 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-Ts
Number of subjects: 15
Study 31356217 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31356375 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial labour analgesia
Number of subjects: 599
Study 31356375 — intervention group
Group type: COMPARATOR
Intervention: No neuraxial labour analgesia (Control)
Number of subjects: 599
Study 31356470 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen 5F peripherally inserted central catheter
Number of subjects: 20
Study 31356470 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen 4F peripherally inserted central catheter
Number of subjects: 20
Study 31356494 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vascular bed area (RVBA) in eyes with DME
Number of subjects: 29
Study 31356494 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 31356494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperfusion area in eyes with DME
Number of subjects: 29
Study 31357748 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 0
Study 31357748 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI monotherapy
Number of subjects: 0
Study 31357748 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV combination therapy
Number of subjects: 0
Study 31357891 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with undiagnosed COPD
Number of subjects: 137
Study 31357891 — intervention group
Group type: COMPARATOR
Intervention: Patients without COPD
Number of subjects: 137
Study 31357993 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 119
Study 31358485 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) administered at peak G-CSF mobilization
Number of subjects: 10
Study 31358485 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF) administered for 5 days
Number of subjects: 10
Study 31358508 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to high volume hospitals (>40 pulmonary embolisms per year)
Number of subjects: 39257
Study 31358508 — intervention group
Group type: COMPARATOR
Intervention: Admission to low volume hospitals (<15 pulmonary embolisms per year)
Number of subjects: 39257
Study 31358597 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 40004
Study 31358597 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial injury after noncardiac surgery (MINS)
Number of subjects: 40004